Critical determinants of neoplastic angiogenesis

Cancer Journal

Volumn 6, Issue SUPPL. 3, 2000, Pages

  Fidler, Isaiah J ^a,b   Singh, Rakesh K ^a   Yoneda, Junya ^a   Kumar, Rakesh ^a   Xu, Lei ^a   Dong, Zhongyun ^a   Bielenberg, Diane R ^a   McCarty, Marya ^a   Ellis, Lee M ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b Box 173 ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENIC FACTOR; BASIC FIBROBLAST GROWTH FACTOR; VASCULOTROPIN;

ANGIOGENESIS; CELL PROLIFERATION; CELL SPREADING; CONFERENCE PAPER; ENDOTHELIUM CELL; HUMAN; METASTASIS; MITOGENESIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; TUMOR VASCULARIZATION;

ANIMALS; CELL TRANSFORMATION, NEOPLASTIC; FEMALE; HUMANS; MICE; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC;

EID: 0033943364     PISSN: 15289117     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (149)

1. Fidler IJ. Critical factors in the biology of human cancer metastasis: twenty-eighth GHA Clowes memorial award lecture. Cancer Res 1990;50:6130-6138.
2. Radinsky R, Aukerman SL, Fidler IJ. The heterogeneous nature of metastatic neoplasms: relevance to biotherapy. In: Oldham RK, ed. Principles of Cancer Biotherapy (3rd ed). Boston: Kluwer Academic, 1998:16-38.
3. Fidler IJ. Modulation of the organ microenvironment for the treatment of cancer metastasis [editorial]. J Natl Cancer Inst 1995;84:1588-1592.
4. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other diseases. Nat Med 1995;1:27-31.
5. Auerbach W, Auerbach R. Angiogenesis inhibition: a review. Pharmacol Ther 1994;63:265-311.
6. Fidler IJ, Ellis LM The implications of angiogenesis for the biology and therapy of cancer metastasis. Cell 1994;79:185-188.
7. Folkman J, Klagsbrun M. Angiogenic factors. Science 1987;235:444-447.
8. Liotta LA, Steeg PS, Stetler-Stevenson WG. Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell 1991;64:327-336.
9. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996;86:353-364.
10. Bouck N, Stellmach V, Hsu SC. How tumors become angiogenic. Adv Cancer Res 1996;69:135-174.
11. Folkman J. Seminars in Medicine of the Beth Israel Hospital, Boston. Clinical applications of research on angiogenesis. N Engl J Med 1995;333:1757-1763.
12. Cockerill GW, Gamble JR, Vadas MA. Angiogenesis: models and modulators. Int Rev Cytol 1995;159:113-160.
13. Leung ZW, Cachianes G, Kuang WJ et al. Vascular endothelia growth factor is a secreted angiogenic mitogen. Science 1989;246:1306-1309.
14. Plate KH, Breier G, Weich HA et al. Vascular endothelial growth factor is a potential tumor angiogenesis factor in human gliomas in vivo. Nature 1992;359:845-848.
15. Dvorak HF, Brown LF, Detmar M et al. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol 1995;146:1029-1039.
16. Koch AE, Polverini PJ, Kunkel SL et al. Interleukin-8 as a macrophage-derived mediator of angiogenesis. Science 1992;258:1798-1801.
17. Singh RK, Gutman M, Radinsky R et al. Expression of interleukin 8 correlates with the metastatic potential of human melanoma cells in nude mice. Cancer Res 1994;54:3242-3247.
18. Yoneda J, Kuniyasu H, Crispens MA et al. Expression of angiogenesis-related genes and progression of human ovarian carcinomas in nude mice. J Natl Cancer Inst 1998;90:447-454.
19. Ishikawa F, Miyazone K, Hellman U et al. Identification of angiogenic activity and the cloning and expression of platelet-derived endothelial cell growth factor. Nature 1989;338:557-562.
20. Bussolino F, Di Renzo MF, Ziche M et al. Hepatocyte growth factor is a potent angiogenic factor which stimulates endothelial cell motility and growth. J Cell Biol 1992;119:629-641.
21. Grant DS, Kleinman HK, Goldberg ID et al. Scatter factor induces blood vessel formation in vivo. Proc Natl Acad Sci USA 1993;90:1937-1941.
22. Heldin C-H. Structural and functional studies on platelet-derived growth factor. EMBO J 1992;11:4251-4259.
23. Risau W, Drexler H, Mironov V et al. Platelet-derived growth factor is angiogenic in vivo. Growth Factors 1992;7:261-266.
24. Holmgren L, Glaser A, Pfeifer-Ohlsson S et al. Angiogenesis during extraembryonic development involves the spatiotemporal control of PDGF ligand and receptor gene expression. Development 1991;113:749-754.
25. Moghaddam A, Zhang H-T, Fan T-PD et al. Thymidine phosphorylase is angiogenic and promotes tumor growth. Proc Natl Acad Sci USA 1995;92:998-1002.
26. Kumar R, Yoneda J, Bucana CD et al. Regulation of distinct steps of angiogenesis by different angiogenic molecules. Int J Oncol 1998;12:749-757.
27. Alon T, Hemo I, Itin A et al. Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity. Nat Med 1995;1:1024-1028.
28. Benjamin LE, Keshet E. Conditioned switching of vascular endothelial growth factor (VEGF) expression in tumors: induction of endothelial cell shedding and regression of hemangioblastoma-like vessels by VEGF withdrawal. Proc Natl Acad Sci USA 1997;94:8761-8766.
29. Senger DR, Galli SJ, Dvorak AM et al. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 1983;219:983-985.
30. Ferrara N, Houck KA, Jakeman LB et al. The vascular endothelial growth factor family of polypeptides. J Cell Biochem 1991;47:211-218.
31. Yoshida A, Anand-Apte B, Zetter BR. Differential endothelial cell migration and proliferation to basic fibroblast growth factor and vascular endothelial growth factor. Growth Factors 1996;13:57-64.
32. Zetter BR. Cell motility in angiogenesis and tumor metastasis. Cancer Invest 1990;8:669-671.
33. Liotta LA, Thorgeirsson UP, Garbisa S. Role of collagenases in tumor cell invasion. Cancer Metastasis Rev 1982;1:277-288.
34. Singh RK, Reich R, Radinsky R et al. Expression of basic fibroblast growth factor is necessary but insufficient for production of metastasis. Int J Oncol 1997;10:23-31.
35. Pepper MS, Ferrara N, Orci L et al. Vascular endothelial growth factor (VEGF) induces plasminogen activators and plasminogen activator inhibitor-1 in microvascular endothelial cells. Biochem Biophys Res Commun 1991;181:902-906.
36. Rosen EM, Grant DS, Kleinman HK et al. Scatter factor (hepatocyte growth factor) is a potent angiogenic factor in vivo. Symp Soc Exp Biol 1993;47:227-234.
37. Stoker M, Perryman M. An epithelial scatter factor released by embryo fibroblasts. J Cell Sci 1985;77:209-223.
38. Vernon RB, Sage H. Between molecules and morphology. Extracellular matrix and creation of vascular form. Am J Pathol 1995;147:873-883.
39. Collins PD, Connolly DT, Williams TJ. Characterization of the increase in vascular permeability induced by vascular permeability factor in vivo. Br J Pharmacol 1993;109:195-199.
40. Feng D, Nagy JA, Hipp J et al. Vesiculo-vacuolar organelles (VVOs) and the regulation of venule permeability to macromolecules by vascular permeability factor, histamine, and serotonin. J Exp Med 1996;183:1981-1986.
41. Roberts WG, Palade GE. Increased microvascular permeability and endothelial fenestration induced by vascular endothelial growth factor. J Cell Sci 1995;108:2369-2379.
42. Shweiki D, Itin A, Soffer D et al. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 1992;359:843-845.
43. Sunderkötter C, Steinbrink K, Goebeler M et al. Macrophages and angiogenesis. J Leukocyte Biol 1994;55:410-422.
44. Slavin J. The role of cytokines in wound healing. J Pathol 1996;178:5-10.
45. Polverini PJ, Leibovich JS. Induction of neovascularization in vivo and endothelial proliferation in vitro by tumor-associated macrophages. Lab Invest 1984;51:635-642.
46. Gutman M, Singh RK, Yoon S et al. Leukocyte-induced angiogenesis and subcutaneous growth of B16 melanoma. Cancer Biother 1994;9:163-170.
47. Leek RD, Harris AL, Lewis CE. Cytokine networks in solid human tumors: regulation of angiogenesis. J Leukocyte Biol 1994;56:423-435.
48. Brown LF, Berse B, Jackman RW et al. Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in adenocarcinomas of the gastrointestinal tract. Cancer Res 1993;53:4727-4735.
49. Yoshiji H, Gomez DE, Shibuya M et al. Expression of vascular endothelial growth factor, its receptor, and other angiogenic factors in human breast cancer. Cancer Res 1996;56:2013-2016.
50. Takahashi Y, Kitadai Y, Bucana CD et al. Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer. Cancer Res 1995;55:3964-3968.
51. Xerri L, Battyeni Z, Grob JJ et al. Expression of FGF1 and FGFR1 in human melanoma tissues. Melanoma Res 1996;6:223-230.
52. Takanami I, Tanaka F, Hashizume T et al. The basic fibroblast growth factor and its receptor in pulmonary adenocarcinomas: an investigation of their expression as prognostic markers. Eur J Cancer 1996;32A:1504-1509.
53. Engerman RL, Pfaffenbach D, Davis MD. Cell turnover of capillaries. Lab Invest 1967;17:738-743.
54. Hobson B, Denekamp J. Endothelial proliferation in tumours and normal tissues: continuous labelling studies. Br J Cancer 1984;49:405-413.
55. Singh RK, Llansa N, Bucana CD et al. Cell density-dependent regulation of basic fibroblast growth factor expression in human renal cell carcinoma cells. Cell Growth Differ 1996;7:397-404.
56. Koura AN, Liu W, Kitadai Y et al. Regulation of vascular endothelial growth factor expression in human colon carcinoma cells by cell density. Cancer Res 1996;56:3891-3894.
57. Kitadai Y, Ellis LM, Takahashi Y et al. Multiparametric in situ messenger RNA hybridization analysis to detect metastasis-related genes in surgical specimens of human colon carcinomas. Clin Cancer Res 1995;1:1095-1102.
58. Swerlick RA, Lee KH, Li LJ et al. Regulation of vascular cell adhesion molecule 1 on human dermal microvascular endothelial cells. J Immunol 1992;149:698-705.
59. Hitraya EG, Tan EM, Rudnicka L et al. Expression of extracellular matrix genes in adult human dermal microvascular endothelial cells and their regulation by heparin and endothelial cell mitogens. Lab Invest 1995;73:393-402.
60. Haraldsen A, Kvale D, Lien B et al. Cytokine-regulated expression of E-selectin, intercellular adhesion molecule-1 (ICAM-1), and vascular cell adhesion molecule-1 (VCAM-1) in human microvascular endothelial cells. J Immunol 1996;156:2558-2565.
61. Auerbach R, Alby L, Morrissey LW et al. Expression of organ-specific antigens on capillary endothelial cells. Microvasc Res 1985;29:401-411.
62. Gumkowski F, Kaminska G, Kaminski M et al. Heterogeneity of mouse vascular endothelium. In vitro studies of lymphatic, large blood vessel and microvascular endothelial cells. Blood Vessels 1987;24:11-23.
63. McLean JW, Fox EA, Baluk P et al. Organ-specific endothelial cell uptake of cationic liposome-DNA complexes in mice. Am J Physiol 1997;273:H387-H404.
64. Dvorak HF. Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N Engl J Med 1986;315:1650-1659.
65. Singh RK, Bucana CD, Gutman M et al. Organ site-dependent expression of basic fibroblast growth factor in human renal cell carcinoma cells. Am J Pathol 1994;145:365-374.
66. Singh RK, Llansa N, Bucana CD et al. Cell density-dependent regulation of basic fibroblast growth factor expression in human renal cell carcinoma cells. Cell Growth Differ 1996;7:397-404.
67. Kitadai Y, Ellis LM, Tucker SL et al. Multiparametric in situ mRNA hybridization analysis to predict disease recurrence in patients with colon carcinoma. Am J Pathol 1996;149:1541-1551.
68. Kitadai Y, Ellis LM, Takahashi Y et al. Multiparametric in situ mRNA hybridization analysis to detect metastasis-related genes in surgical specimens of human colon carcinoma. Clin Cancer Res 1995;1:1095-1102.
69. Herlyn M. Human melanoma: development and progression. Cancer Metastasis Rev 1990;9:101-112.
70. Singh RK, Bucana CD, Llansa N et al. Cell density-dependent modulation of basic fibroblast growth factor expression by human interferon-β. Int J Oncol 1996;8:649-656.
71. Gutman M, Singh, RK, Xie K et al. Regulation of interleukin-8 expression in human melanoma cells by the organ environment. Cancer Res 1995;55:2470-2475.
72. Shweiki D, Itin A, Soffer D et al. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 1992;359:843-848.
73. Rak J, Filmus J, Finkenzeller G et al. Oncogenes as inducers of tumor angiogenesis. Cancer Metastasis Rev 1995;14:263-277.
74. Takahashi Y, Bucana CD, Liu W et al. Platelet-derived endothelial cell growth factor in human colon cancer angiogenesis: role of infiltrating cells. J Natl Cancer Inst 1996;88:1146-1151.
75. Takahashi Y, Mai M, Wilson MR et al. Site-dependent expression of vascular endothelial growth factor, angiogenesis and proliferation in human gastric carcinoma. Int J Oncol 1996;8:701-705.
76. Brocker EG, Rekenfeld C, Hamm H et al. Macrophages in melanocytic naevi. Arch Dermatol Res 1992;284:127-131.
77. Fidler IJ, Gersten DM, Kripke ML. Influence of immune status on the metastasis of three murine fibrosarcomas of different immunogenicities. Cancer Res 1979;39:3816-3821.
78. Sidky YA, Auerbach R. Lymphocyte-induced angiogenesis in tumor-bearing mice. Science 1976;192:1237-1238.
79. Koura AN, Liu W, Kitadai Y et al. Regulation of vascular endothelial growth factor expression in human colon carcinoma cells by cell density. Cancer Res 1996;56:3891-3894.
80. Noh R, Karp GI, Devereux DF. The effects of doxorubicin and mitoxantrone on wound healing. Cancer Chemother Pharmacol 1991;29:141-144.
81. Fidler IJ. Lymphocytes are not only immunocytes [editorial]. Biomedicine 1980;32:1-3.
82. Yoneda J, Killion JJ, Bucana CD et al. Angiogenesis and growth of murine colon carcinoma are dependent on infiltrating leukocytes. Cancer Biother Radiopharm 1999;14:221-230.
83. Meininger CJ, Zetter BR. Mast cells and angiogenesis. Semin Cancer Biol 1992;3:73-79.
84. Polverini PS, Cotran RS, Gimbrone MA Jr et al. Activated macrophages induce vascular proliferation. Nature 1977; 269:804-805.
85. Sunderkötter C, Goebeler M, Schulze-Osthoff K et al. Macrophage-derived angiogenesis factors. Pharmacol Ther 1991;51:195-216.
86. Polverini PJ. How the extracellular matrix and macrophages contribute to angiogenesis-dependent diseases. Eur J Cancer 1996;32A:2430-2437.
87. Ingber D. Extracellular matrix and cell shape: potential control points for inhibition of angiogenesis. J Cell Biochem 1991;47:236-241.
88. Ingber DE, Folkman J. How does extracellular matrix control capillary morphogenesis? Cell 1989;58:803-805.
89. DiPietro LA, Polverini PJ. Angiogenic macrophages produce the angiogenic inhibitor thrombospondin 1. Am J Pathol 1993;143:678-684.
90. Lingen MW, Polverini PJ, Bouck N. Inhibition of squamous cell carcinoma angiogenesis by direct interaction of retinoic acid with endothelial cells. Lab Invest 1996;74:476-483.
91. Lingen MW, Polverini PJ, Bouck N. Retinoic acid induces cells cultured from oral squamous cell carcinomas to become anti-angiogenic. Am J Pathol 1996;149:247-258.
92. O'Reilly MS, Holmgren L, Shing Y et al. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 1994;79:315-328.
93. Dong Z, Kumar R, Yang X et al. Macrophage-derived metallo-elastase is responsible for the generation of angiostatin in Lewis lung carcinoma. Cell 1997;88:801-810.
94. Kumar R, Dong Z, Fidler IJ. Differential regulation of metallo-elastase activity in murine peritoneal macrophages by granulocyte-macrophage colony-stimulating factor and macrophage colony-stimulating factor. J Immunol 1996;157:5104-5111.
95. Ezekowitz RAB, Mulliken JB, Folkman J. Interferon alfa-2a therapy for life-threatening hemangiomas of infancy. N Engl J Med 1992;326:1456-63.
96. White CW, Sondheimer HM, Crouch EC et al. Treatment of pulmonary hemangiomatosis with recombinant interferon-α-2a. N Engl J Med 1989;320:1197-1200.
97. Orchard PJ, Smith CM, Woods WG et al. Treatment of heamangioendotheliomas with alpha interferon. Lancet 1989;ii(8662):565-567.
98. Ricketts RR, Hatley RM, Corden BJ et al. Interferon-α-2a for the treatment of complex hemangiomas of infancy and childhood. Ann Surg 1994;219:605-614.
99. Ohlms LA, Jones DT, McGill TJ et al. Interferon-α-2a therapy for airway hemangiomas. Ann Otol Rhinol Laryngol 1994;103:1-8.
100. Bielenberg DR, Bucana CD, Sanchez R et al. Progressive growth of infantile cutaneous hemangiomas is directly correlated with hyperplasia and angiogenesis of adjacent epidermis and inversely correlated with expression of the endogenous angiogenesis inhibitor, IFN-β. Int J Oncol 1999;14:401-408.
101. Bielenberg DR, McCarty MF, Bucana CD et al. Expression of interferon-β is associated with growth arrest of murine and human epidermal cells. J Invest Dermatol 1999;112:802-809.
102. Bielenberg DR, Bucana CD, Sanchez R et al. Molecular regulation of UV-B-induced cutaneous angiogenesis. J Invest Dermatol 1998;111:864-872.
103. Uze G, Lutfalla G, Mogensen KE. α and β interferons and their receptor and their friends and relations. J Interferon Cytokine Res 1995;15:3-26.
104. Yaar M, Karassik RL, Schnipper LE et al. Effects of alpha and beta interferons on cultured human keratinocytes. J Invest Dermatol 1985;85:70-74.
105. Tamm I, Lin SL, Pfeffer LM et al. Interferons α and β as cellular regulatory molecules. Interferon 1987;9:13-74.
106. Rossi G. Interferons and cell differentiation. Interferon 1985;6:31-68.
107. 17 in a human colon carcinoma cell line. Cancer Chemother Pharmacol 1992;30:12-20.
108. Resnitzky D, Yarden A, Zipori D et al. Autocrine β-related interferon controls c-myc suppression and growth arrest during hematopoietic cell differentiation. Cell 1986;46:31-40.
109. de Maeyer-Guignard J, de Maeyer E. Immunomodulation by interferons: recent developments. Interferon 1985;6:69-91.
110. Strander H. Interferon treatment of human neoplasia: effects on the immune system. Adv Cancer Res 1986;46:36-57.
111. Gresser I, Carnaud C, Maury C et al. Host humoral and cellular immune mechanisms in the continued suppression of Friend erythroleukemia metastases after interferon α/β treatment in mice. J Exp Med 1991;173:1193-1203.
112. Gresser I. Antitumor effects of interferon. Acta Oncol 1989;28:347-353.
113. Ferrantini M, Proietti E, Santodonato L et al. α1-Interferon gene transfer into metastatic Friend leukemia cells abrogated tumorigenicity in immunocompetent mice: antitumor therapy by means of interferon-producing cells. Cancer Res 1993;53:1107-1112.
114. Gresser I, Belardelli F, Maury C et al. Injection of mice with antibody to interferon enhances the growth of transplantable murine tumors. J Exp Med 1983;158:2095-2107.
115. Gutterman JU. Cytokine therapeutics: lessons from interferon-α. Proc Natl Acad Sci USA 1994;91:1198-1205.
116. Gresser I. How does interferon inhibit tumor growth? Interferon 1985;6:93-126.
117. Fleischmann WR, Fleischmann CM. Mechanisms of interferons antitumor actions. In: Baron S, Coppenhaver DH, Dianzani F et al, eds. Interferon: Principles and Medical Applications. Galveston, TX: University of Texas Press, 1992:299-309.
118. Gorlach A, Herter P, Hentschel H et al. Effects of nIFN-β and rIFN-γ on growth and morphology of two human melanoma cell lines: comparison between two-and three-dimensional culture. Int J Cancer 1994;56:249-254.
119. Johns TG, Mackay IR, Callister KA et al. Antiproliferative potencies of interferons on melanoma cell lines and xenografts: higher efficacy of interferon-bera. J Natl Cancer Inst 1992;84:1185-1190.
120. Sica G, Fabbroni L, Castagnetta L et al. Antiproliferative effect of interferons on human prostate carcinoma cell lines. Urol Res 1989;17:111-115.
121. Heyns AP, Eldor A, Vlodavsky I et al. The antiproliferative effect of interferon and the mitogenic activity of growth factors are independent cell cycle events. Studies with vascular smooth muscle cells and endothelial cells. Exp Cell Res 1985;161:297-306.
122. Friesel R, Komoriya A, Maciag T. Inhibition of endothelial cell proliferation by gamma-interferon. J Cell Biol 1987;104:689-696.
123. Ruszczak Z, Detmar M, Imcke E et al. Effects of rIFN-α, -β, and -γ on the morphology, proliferation, and cell surface antigen expression of human dermal microvascular endothelial cells in vitro. J Invest Dermatol 1990;95:693-699.
124. Hicks C, Breit SN, Penny R. Response of microvascular endothelial cells to biological response modifiers. Immunol Cell Biol 1989;67(5):271-277.
125. Groopman JE, Gottlieb MS, Goodman J et al. Recombinant alpha-2 interferon therapy for Kaposi's sarcoma associated with the acquired immunodeficiency syndrome. Ann Intern Med 1984;100:671-676.
126. Real FX, Oettgen HF, Krown SE. Kaposi's sarcoma and the acquired immunodeficiency syndrome: treatment with high and low doses of recombinant leukocyte A interferon. J Clin Oncol 1986;4:544-551.
127. Rios A, Mansell PW, Newell GR et al. Treatment of acquired immunodeficiency syndrome-related Kaposi's sarcoma with lymphoblastoid interferon. J Clin Oncol 1985;3:506-512.
128. Mitsuyasu RT. Interferon alpha in the treatment of AIDS-related Kaposi's sarcoma. Br J Haematol 1991;79[suppl 1]:69-73.
129. Legha SS. The role of interferon alfa in the treatment of metastatic melanoma. Semin Oncol 1997;24:S24-31.
130. Tucker SB. Interferon-alpha treatment of basal cell and squamous cell skin tumors. Cancer Bull 1993;45:270-274.
131. Stadler WM, Kuzel TM, Raghavan D et al. Metastatic bladder cancer: advances in treatment. Eur J Cancer 1997;33[suppl]:S23-26.
132. Nanus DM, Schmitz-Drager BJ, Motzer RJ et al. Expression of basic fibroblast growth factor in primary human renal tumors: correlation with poor survival. J Natl Cancer Inst 1994;85:1597-1599.
133. Nguyen M, Watanabe H, Budson AE et al. Elevated levels of an angiogenic peptide, basic fibroblast growth factor, in the urine of patients with a wide spectrum of cancers. J Natl Cancer Inst 1994;86:356-361.
134. O'Brien TS, Smith K, Cranston D et al. Urinary basic fibroblast growth factor in patients with bladder cancer and benign prostatic hypertrophy. Br J Urol 1995;76:311-314.
135. Singh RK, Gutman M, Bucana CD et al. Interferons alpha and beta downregulate the expression of basic fibroblast growth factor in human carcinomas. Proc Natl Acad Sci USA 1995;92:4562-4566.
136. Dinney CPN, Bielenberg DR, Reich R et al. Inhibition of basic fibroblast growth factor expression, angiogenesis, and growth of human bladder carcinoma in mice by systemic interferon-alpha administration. Cancer Res 1998;58:808-814.
137. Brouty-Boye D, Zetter BR. Inhibition of cell motility by interferon. Science 1980;208:516-518.
138. Fukuzawa K, Horikoshi T. Inhibitory effect of human fibroblast interferon (HuIFN-β) on the growth and invasive potential of cultured human melanoma cells in vitro. Br J Dermatol 1992;126:324-330.
139. Stout AJ, Gresser I, Thompson WD. Inhibition of wound healing in mice by local interferon α/β injection. Int J Exp Pathol 1993;74:79-85.
140. Dvorak HF, Gresser I. Microvascular injury in pathogenesis of interferon-induced necrosis of subcutaneous tumors in mice. J Natl Cancer Inst 1989;81:497-502.
141. Sidky YA, Borden EC. Inhibition of angiogenesis by interferons: effects on tumor-and lymphocyte-induced vascular responses. Cancer Res 1987;47:5155-5161.
142. Singh RK, Gutman M, Llansa N et al. Interferon-β prevents the upregulation of interleukin-8 expression in human melanoma cells. J Interferon Cytokine Res 1996;16:577-584.
143. Fabra A, Nakajima M, Bucana CD et al. Modulation of the invasive phenotype of human colon carcinoma cells by organ-specific fibroblasts of nude mice. Differentiation 1992;52:101-110.
144. Gohji K, Nakajima M, Fabra A et al. Regulation of gelatinase production in metastatic renal cell carcinoma by organ-specific fibroblasts. Jpn J Cancer Res 1994;85:152-160.
145. Bielenberg DR, Fidler IJ, Bucana CD. Constitutive expression of interferon-beta in differentiated epithelial cells exposed to environmental stimuli. Cancer Biother Radiopharm 1998;13:375-382.
146. Bielenberg DR, McCarty MF, Bucana CD et al. Expression of interferon-β is associated with growth arrest of murine and human epidermal cells. J Invest Dermatol 1999;112:802-809.
147. Xu L, Xie K, Fidler IJ. Therapy of human ovarian cancer by transfection with the murine interferon beta gene: role of macrophage-inducible nitric oxide synthase. Hum Gene Ther 1998;9:2699-2708.
148. Xie K, Bielenberg D, Huang S et al. Abrogation of tumorigenicity and metastasis of murine and human tumor cells by transfection with the murine IFN-beta gene: possible role of nitric oxide. Clin Cancer Res 1997;3:2283-2294.
149. Dong Z, Greene G, Pettaway C et al. Suppression of angiogenesis, tumorigenicity, and metastasis by human prostate cancer cells engineered to produce interferon-β. Cancer Res 1999;59:872-879.